Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone936-355-1910
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.37 million
Profitability
Miscellaneous
Employees14
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Aravive (NASDAQ:ARAV) Frequently Asked Questions
What is Aravive's stock symbol?
Aravive trades on the NASDAQ under the ticker symbol "ARAV."
How were Aravive's earnings last quarter?
Aravive Inc (NASDAQ:ARAV) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.27) EPS for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.27. The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $1 million. View Aravive's Earnings History.
When is Aravive's next earnings date?
What price target have analysts set for ARAV?
3 brokerages have issued twelve-month price targets for Aravive's stock. Their forecasts range from $14.00 to $18.00. On average, they expect Aravive's share price to reach $15.67 in the next twelve months. This suggests a possible upside of 138.5% from the stock's current price. View Analyst Price Targets for Aravive.
What is the consensus analysts' recommendation for Aravive?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aravive.
Has Aravive been receiving favorable news coverage?
News articles about ARAV stock have trended somewhat positive on Monday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aravive earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Aravive.
Are investors shorting Aravive?
Aravive saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 32,000 shares, an increase of 92.8% from the August 30th total of 16,600 shares. Based on an average daily trading volume, of 31,200 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.6% of the company's stock are short sold. View Aravive's Current Options Chain.
Who are some of Aravive's key competitors?
Some companies that are related to Aravive include Molecular Templates (MTEM), Ardelyx (ARDX), Kiniksa Pharmaceuticals (KNSA), Atreca (BCEL), Cyclerion Therapeutics (CYCN), Rigel Pharmaceuticals (RIGL), Recro Pharma (REPH), Geron (GERN), Dynavax Technologies (DVAX), BIOFRONTERA AG/ADR (BFRA), Puma Biotechnology (PBYI), Forty Seven (FTSV), resTORbio (TORC), ProQR Therapeutics (PRQR) and Seres Therapeutics (MCRB).
What other stocks do shareholders of Aravive own?
Who are Aravive's key executives?
Aravive's management team includes the folowing people:
- Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)
- Dr. Jeffrey L. Cleland, Co-Founder (Age 54)
- Dr. Joshua Silverman Ph.D., Co-Founder
- Mr. Vinay Shah, Chief Financial Officer
- Dr. Gail F. McIntyre, Chief Scientific Officer (Age 56)
How do I buy shares of Aravive?
Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aravive's stock price today?
One share of ARAV stock can currently be purchased for approximately $6.57.
How big of a company is Aravive?
Aravive has a market capitalization of $74.11 million and generates $1.37 million in revenue each year. The company earns $-76,330,000.00 in net income (profit) each year or ($10.64) on an earnings per share basis. Aravive employs 14 workers across the globe.View Additional Information About Aravive.
What is Aravive's official website?
How can I contact Aravive?
Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]
MarketBeat Community Rating for Aravive (NASDAQ ARAV)
MarketBeat's community ratings are surveys of what our community members think about Aravive and other stocks. Vote "Outperform" if you believe ARAV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAV will underperform the S&P 500 over the long term. You may vote once every thirty days.
